沙库巴曲缬沙坦治疗慢性心力衰竭临床研究

目的 观察沙库巴曲缬沙坦治疗慢性心力衰竭(CHF)的临床效果.方法 选取2018年2月至2019年7月在朝阳市中心医院心内科住院治疗的CHF患者120例为研究对象,随机分为对照组(n=60)及观察组(n=60).对照组患者采用包括血管扩张剂、利尿剂、β受体阻滞剂、血管紧张素转化酶抑制剂(ACEI)或血管紧张素II受体阻...

Clinical researches of sacubitril/valsartan for chronic heart failure

Objective To observe the clinical effect of sacubatro and Valsartan in the treatment of chronic heart failure(CHF).Methods 120 CHF patients hospitalized in the Department of Cardiology of Chaoyang Central Hospital from February 2018 to July 2019 were selected as the research objects and randomly divided into control group(n=60)and observation group(n=60).The control group was treated with conventional anti heart failure therapy including vasodilator,diuretic,β-blocker,angiotensin converting enzyme inhibitor(ACEI)or angiotensin II receptor blocker(ARB),aldosterone receptor blocker,etc.,and the treatment plan was adjusted in time according to the symptoms and signs of the patients;the observation group was treated with ACEI/ARB instead of sacubatre,valsartan sodium,starting agent The dosage was 25 mg/time,twice a day.According to the blood pressure of the patients,the dosage was increased to the maximum tolerated dose.Both groups were treated for 6 months.The clinical efficacy,left ventricular ejection fraction(LVEF),stroke volume(SV),cardiac output(CO)and left ventricular short axis shortening rate(FS)were compared between the two groups;the expression of serum inflammatory factors IL-1β,IL-6,IL-18,IL-33 and IL-37 were measured;the treatment period was recorded The number of hospitalizations,length of stay,and the incidence of adverse reactions were analyzed.Results The total effective rate of the observation group was 93.33%,which was higher than 73.33%of the control group(P<0.05).After treatment,the cardiac function indexes(LVEF,SV,Co,FS)and inflammatory factors(IL-1β,IL-6,IL-18,IL-33,IL-37)of the two groups were significantly improved(P<0.05),and the observation group was significantly better than the control group(P<0.05).The incidence of adverse reactions in the two groups was similar(P>0.05);compared with the control group,the number and length of hospital stay in the observation group were significantly less(P<0.05).Conclusion Sacubitril/valsartan is effective and safe in treating chronic heart failure,and could alleviate inflammation.